Market by Type, Disease, and Regional Outlook | Forecast 2023-2030
Proteins are the body’s most essential element,
playing a pivotal role in providing structural support, preventing diseases, and
coordinating cell signals. However, there are difficulties in providing
biologically active proteins to the intended cells and organs. To regulate
protein transport, cutting-edge methods like biomedical engineering are
employed. Bioengineered proteins, also called recombinant proteins, are
produced through genetic modification. They help treat injuries, hormonal
problems, cancers, and persistent illnesses like asthma, diabetes, and heart
disease.
According to Triton Market Research’s analysis, the Global Bioengineered Protein Drugs Market was valued at $XX million in 2022 and is anticipated to reach $XX million by 2030, growing at a CAGR of 7.7% during the forecast period 2023-2030.
Click here to check out our blog on the Global Bioengineered Protein Drugs Market
MARKET PERFORMANCE: DRIVERS,
CHALLENGES, AND OPPORTUNITIES
A
rising incidence of chronic diseases, targeted drug delivery methods, and
minimum side effects of these drugs drive the market for bioengineered protein
drugs. There has been a
rapid increase in the incidence of chronic ailments like diabetes, cancer,
heart disease, asthma, etc., in recent times. The COVID-19 pandemic’s
mitigation strategies also severely impacted physical activity, resulting in
obesity and chronic diseases like type 2 diabetes (T2D) and endometrial cancer.
According to the National Center for Chronic Disease Prevention and Health
Promotion, 6 in 10 adults in the US are diagnosed with a chronic disease. In
this regard, bioengineered protein drugs have emerged as powerful therapeutic
agents to destroy tumors and activate the immune system to respond to cancer.
Fusion proteins, antibodies, and vaccines are the main drugs used in cancer
treatment.
However,
the high costs associated with these drugs and the complex treatment processes
are likely to hamper the growth of the studied market during the forecast
period. Bioengineered
protein drugs are developed in labs using cultured cells, contributing to high
prices. Purifying these drugs, which can make up as much as 80% of the
manufacturing costs, is one of the main expenses. These high costs make it
difficult for a wider population to afford these medications.
Nevertheless,
a surge in preference for preventive care, increasing healthcare expenditure,
and technological innovations in protein engineering offer potential growth
opportunities to the market.
Preventive care enables the detection of serious illness at an initial stage,
helping avoid potential health risks. A popular method of preventive care
includes vaccination, which significantly offers expansion opportunities to the
bioengineered protein drugs market.
Report scope can be customized per your requirements - Request Free Sample Report
KEY
GEOGRAPHIES COVERED:
• North America: United States and Canada
• Europe: United Kingdom, France,
Germany, Spain, Italy, Poland, and Rest of Europe
• Asia-Pacific: China, Japan, India,
Australia & New Zealand, South Korea, ASEAN Countries, and Rest of
Asia-Pacific
• Latin America: Brazil, Mexico, and Rest
of Latin America
• Middle East and Africa: Saudi Arabia,
Turkey, United Arab Emirates, South Africa, and Rest of Middle East &
Africa
SEGMENTATION ANALYSIS –
BIOENGINEERED PROTEIN DRUGS MARKET:
• Market by Type:
o Monoclonal
Antibodies
o Peptide
Hormones
o Vaccines
(Excluding COVID-19)
o Blood
Factors and Peptide Antibiotics
o Fusion
Proteins
o Cytokines
o Therapeutic
Enzymes
Monoclonal antibodies are classes of synthetic antibodies that function
similarly to the human immune system. They are used to address a variety of
illnesses, including cancer, immune system disorders, and viral infections in
young children. Moreover, these antibodies are popular in providing targeted
cancer treatment. According to WHO, cancer is a leading cause of mortality,
leading to 10 million deaths in 2020. These factors are expected to result in
the greater application of monoclonal antibodies.
• Market by Disease:
o Autoimmune
Diseases and Other Immunodeficiency Disorders
o Solid
Tumors
o Diabetes
o Infectious
Diseases
o Blood
Disorders
o Growth
Hormone Disorders, Enzyme Disorders, and Infertility
o Other
Diseases
According to the International Diabetes Federation, in 2021,
approximately 537 million adults aged between 20-27 years suffered from
diabetes. Moreover, it was responsible for around 6.7 million deaths in 2021.
Hence, this increasing incidence of diabetes demands a greater preference for
bioengineered protein drugs. Oral administration of peptide drugs is a
potential approach for diabetes mellitus.
COMPETITIVE LANDSCAPE
The bioengineered protein drugs market by company profile helps dive
into data about the key players in this industry. The strategic initiatives for
each of the companies considered have been covered in detail.
Agreements
(March 2023): Arzeda and Takeda
This partnership aims to utilize AI-based
protein design to enhance the properties of protein biologics. The companies
aim to also improve Takeda’s research on therapeutic proteins.
Product
Launch (March 2023): Protalix Biotherapeutics
Protalix BioTherapeutics Inc, a
biopharmaceutical business, launched PRX-115, a PEGylated recombinant uricase
developed on the ProCellEx® platform to manage severe gout.
KEY BENEFITS OF THE REPORT:
●
Triton Market Research has a collective experience of 25-30 years
in the industry, with its analysts and experts encompassing the most infallible
research methodology for its market intelligence and industry analysis.
●
Our research methodology helps in achieving a broader consensus of
the market size, shape, and industry trends within each industry segment.
●
The strategy adopted in designing the research methodology
includes the amalgamation of the information assembled from primary and
secondary sources, with the assistance of analytical tools to construct the
forecast and predictive models.
●
The scope of the market report comprises the current scenario of
the global bioengineered protein drugs market, along with a detailed overview
of the industry outlook, market dynamics, segmentation analysis, regional
outlook, and competitive landscape for the period 2023-2030.
FAQs:
1.)
What are the major functions of
cytokines?
Cytokines play a critical role in
chemically induced tissue injury repair, cancer development and progression,
cell replication and apoptosis control, and immune response modulation, such as
sensitization.
2.)
What are some of the recombinant
proteins?
Insulin to treat diabetes, bovine
used as a growth hormone, Antithrombin III to prevent blood clots, and human recognition growth
hormone are some bioengineered proteins used in medical practice.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. GLOBAL
BIOENGINEERED PROTEIN DRUGS MARKET - SUMMARY
2. INDUSTRY
OUTLOOK
2.1. IMPACT
OF COVID-19 ON THE BIOENGINEERED PROTEIN DRUGS MARKET
2.2. KEY
INSIGHTS
2.2.1. A SURGE IN PREFERENCE FOR PREVENTIVE CARE
2.2.2. INVESTMENTS IN RESEARCH AND DEVELOPMENT FOR
BIOENGINEERED PROTEIN DRUGS
2.2.3. RISE IN FDA APPROVALS FOR THESE DRUGS
2.3. PORTER’S
FIVE FORCES ANALYSIS
2.3.1. THREAT
OF NEW ENTRANTS
2.3.2. THREAT
OF SUBSTITUTES
2.3.3. BARGAINING
POWER OF BUYERS
2.3.4. BARGAINING
POWER OF SUPPLIERS
2.3.5. THREAT
OF COMPETITIVE RIVALRY
2.4. MARKET
ATTRACTIVENESS INDEX
2.5. VENDOR
SCORECARD
2.6. REGULATORY
FRAMEWORK
2.7. KEY
MARKET STRATEGIES
2.7.1. ACQUISITIONS
2.7.2. PRODUCT
LAUNCHES
2.7.3. COLLABORATIONS
2.7.4. INVESTMENTS
& EXPANSIONS
2.8. MARKET
DRIVERS
2.8.1. INCREASING
INCIDENCE OF CHRONIC DISEASES
2.8.2. MINIMUM
SIDE EFFECTS OF BIOENGINEERED PROTEIN DRUGS
2.8.3. TARGETED
DRUG DELIVERY METHODS FOR SUCCESSFUL TREATMENT
2.9. MARKET
CHALLENGES
2.9.1. HIGH
COSTS ASSOCIATED WITH BIOENGINEERED PROTEIN DRUGS
2.9.2. COMPLICATIONS
DURING TREATMENTS
2.10. MARKET
OPPORTUNITIES
2.10.1. INCREASING
HEALTHCARE EXPENDITURE
2.10.2. ADVANCEMENTS
IN BIOTECHNOLOGY AND PROTEIN ENGINEERING
3. GLOBAL
BIOENGINEERED PROTEIN DRUGS MARKET OUTLOOK - BY TYPE
3.1. MONOCLONAL
ANTIBODIES
3.2. PEPTIDE
HORMONES
3.3. VACCINES
(EXCLUDING COVID-19)
3.4. BLOOD
FACTORS AND PEPTIDE ANTIBIOTICS
3.5. FUSION
PROTEINS
3.6. CYTOKINES
3.7. THERAPEUTIC
ENZYMES
4. GLOBAL
BIOENGINEERED PROTEIN DRUGS MARKET OUTLOOK - BY DISEASE
4.1. AUTOIMMUNE
DISEASES AND OTHER IMMUNODEFICIENCY DISORDERS
4.2. SOLID
TUMORS
4.3. DIABETES
4.4. INFECTIOUS
DISEASES
4.5. BLOOD
DISORDERS
4.6. GROWTH
HORMONE DISORDERS, ENZYME DISORDERS, AND INFERTILITY
4.7. OTHER
DISEASES
5. GLOBAL
BIOENGINEERED PROTEIN DRUGS MARKET – BY REGIONAL OUTLOOK
5.1. NORTH
AMERICA
5.1.1. MARKET
BY TYPE
5.1.2. MARKET
BY DISEASE
5.1.3. COUNTRY
ANALYSIS
5.1.3.1. UNITED
STATES
5.1.3.2. CANADA
5.2. EUROPE
5.2.1. MARKET
BY TYPE
5.2.2. MARKET
BY DISEASE
5.2.3. COUNTRY
ANALYSIS
5.2.3.1. UNITED
KINGDOM
5.2.3.2. GERMANY
5.2.3.3. FRANCE
5.2.3.4. SPAIN
5.2.3.5. ITALY
5.2.3.6. POLAND
5.2.3.7. REST
OF EUROPE
5.3. ASIA-PACIFIC
5.3.1. MARKET
BY TYPE
5.3.2. MARKET
BY DISEASE
5.3.3. COUNTRY
ANALYSIS
5.3.3.1. CHINA
5.3.3.2. JAPAN
5.3.3.3. INDIA
5.3.3.4. SOUTH
KOREA
5.3.3.5. ASEAN
COUNTRIES
5.3.3.6. AUSTRALIA
& NEW ZEALAND
5.3.3.7. REST
OF ASIA-PACIFIC
5.4. LATIN
AMERICA
5.4.1. MARKET
BY TYPE
5.4.2. MARKET
BY DISEASE
5.4.3. COUNTRY
ANALYSIS
5.4.3.1. BRAZIL
5.4.3.2. MEXICO
5.4.3.3. REST
OF LATIN AMERICA
5.5. MIDDLE
EAST AND AFRICA
5.5.1. MARKET
BY TYPE
5.5.2. MARKET
BY DISEASE
5.5.3. COUNTRY
ANALYSIS
5.5.3.1. UNITED
ARAB EMIRATES
5.5.3.2. SAUDI
ARABIA
5.5.3.3. TURKEY
5.5.3.4. SOUTH
AFRICA
5.5.3.5. REST
OF MIDDLE EAST & AFRICA
6. COMPETITIVE
LANDSCAPE
6.1. ABBOTT
LABORATORIES
6.2. AMGEN
INC
6.3. BAXTER
INTERNATIONAL INC
6.4. BAYER
HEALTHCARE PHARMACEUTICALS LLC
6.5. F HOFFMANN-LA
ROCHE
6.6. GLAXOSMITHKLINE
6.7. MERC &
CO INC
6.8. ELI
LILLY AND COMPANY
6.9. FRESENIUS
KABI
6.10. JOHNSON
& JOHNSON
7. RESEARCH
METHODOLOGY & SCOPE
7.1. RESEARCH
SCOPE & DELIVERABLES
7.2. SOURCES OF DATA
7.3. RESEARCH
METHODOLOGY
TABLE
1: GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET, BY REGIONAL OUTLOOK, 2023-2030
(IN $ MILLION)
TABLE
2: VENDOR SCORECARD
TABLE
3: LIST OF ACQUISITIONS
TABLE
4: LIST OF PRODUCT LAUNCHES
TABLE
5: LIST OF COLLABORATIONS
TABLE
6: LIST OF INVESTMENTS & EXPANSIONS
TABLE
7: GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET, BY TYPE, 2023-2030 (IN $ MILLION)
TABLE
8: GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET, BY DISEASE, 2023-2030 (IN $
MILLION)
TABLE
9: GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET, BY REGIONAL OUTLOOK, 2023-2030
(IN $ MILLION)
TABLE
10: NORTH AMERICA BIOENGINEERED PROTEIN DRUGS MARKET, BY COUNTRY OUTLOOK,
2023-2030 (IN $ MILLION)
TABLE
11: NORTH AMERICA BIOENGINEERED PROTEIN DRUGS MARKET, BY TYPE, 2023-2030 (IN $
MILLION)
TABLE
12: NORTH AMERICA BIOENGINEERED PROTEIN DRUGS MARKET, BY DISEASE, 2023-2030 (IN
$ MILLION)
TABLE
13: EUROPE BIOENGINEERED PROTEIN DRUGS MARKET, BY COUNTRY OUTLOOK, 2023-2030
(IN $ MILLION)
TABLE
14: EUROPE BIOENGINEERED PROTEIN DRUGS MARKET, BY TYPE, 2023-2030 (IN $
MILLION)
TABLE
15: EUROPE BIOENGINEERED PROTEIN DRUGS MARKET, BY DISEASE, 2023-2030 (IN $
MILLION)
TABLE
16: ASIA-PACIFIC BIOENGINEERED PROTEIN DRUGS MARKET, BY COUNTRY OUTLOOK,
2023-2030 (IN $ MILLION)
TABLE
17: ASIA-PACIFIC BIOENGINEERED PROTEIN DRUGS MARKET, BY TYPE, 2023-2030 (IN $
MILLION)
TABLE
18: ASIA-PACIFIC BIOENGINEERED PROTEIN DRUGS MARKET, BY DISEASE, 2023-2030 (IN
$ MILLION)
TABLE
19: LATIN AMERICA BIOENGINEERED PROTEIN DRUGS MARKET, BY COUNTRY OUTLOOK,
2023-2030 (IN $ MILLION)
TABLE
20: LATIN AMERICA BIOENGINEERED PROTEIN DRUGS MARKET, BY TYPE, 2023-2030 (IN $
MILLION)
TABLE
21: LATIN AMERICA BIOENGINEERED PROTEIN DRUGS MARKET, BY DISEASE, 2023-2030 (IN
$ MILLION)
TABLE
22: MIDDLE EAST AND AFRICA BIOENGINEERED PROTEIN DRUGS MARKET, BY COUNTRY
OUTLOOK, 2023-2030 (IN $ MILLION)
TABLE
23: MIDDLE EAST AND AFRICA BIOENGINEERED PROTEIN DRUGS MARKET, BY TYPE,
2023-2030 (IN $ MILLION)
TABLE
24: MIDDLE EAST AND AFRICA BIOENGINEERED PROTEIN DRUGS MARKET, BY DISEASE,
2023-2030 (IN $ MILLION)
FIGURE
1: KEY MARKET TRENDS
FIGURE
2: PORTER’S FIVE FORCES ANALYSIS
FIGURE
3: MARKET ATTRACTIVENESS INDEX
FIGURE
4: GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET, BY TYPE, 2022 & 2030 (IN %)
FIGURE
5: GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET, BY MONOCLONAL ANTIBODIES,
2023-2030 (IN $ MILLION)
FIGURE
6: GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET, BY PEPTIDE HORMONES, 2023-2030
(IN $ MILLION)
FIGURE
7: GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET, BY VACCINES (EXCLUDING COVID-19),
2023-2030 (IN $ MILLION)
FIGURE
8: GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET, BY BLOOD FACTORS AND PEPTIDE
ANTIBIOTICS, 2023-2030 (IN $ MILLION)
FIGURE
9: GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET, BY FUSION PROTEINS, 2023-2030 (IN
$ MILLION)
FIGURE
10: GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET, BY CYTOKINES, 2023-2030 (IN $
MILLION)
FIGURE
11: GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET, BY THERAPEUTIC ENZYMES,
2023-2030 (IN $ MILLION)
FIGURE
12: GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET, BY DISEASE, 2022 & 2030 (IN
%)
FIGURE
13: GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET, BY AUTOIMMUNE DISEASES AND OTHER
IMMUNODEFICIENCY DISORDERS, 2023-2030 (IN $ MILLION)
FIGURE
14: GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET, BY SOLID TUMORS, 2023-2030 (IN $
MILLION)
FIGURE
15: GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET, BY DIABETES, 2023-2030 (IN $
MILLION)
FIGURE
16: GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET, BY INFECTIOUS DISEASES,
2023-2030 (IN $ MILLION)
FIGURE
17: GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET, BY BLOOD DISORDERS, 2023-2030
(IN $ MILLION)
FIGURE
18: GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET, BY GROWTH HORMONE DISORDERS,
ENZYME DISORDERS, AND INFERTILITY, 2023-2030 (IN $ MILLION)
FIGURE
19: GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET, BY OTHER DISEASES, 2023-2030 (IN
$ MILLION)
FIGURE
20: GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET, BY REGIONAL OUTLOOK, 2022 &
2030 (IN %)
FIGURE
21: NORTH AMERICA BIOENGINEERED PROTEIN DRUGS MARKET, BY COUNTRY OUTLOOK, 2022
& 2030 (IN %)
FIGURE
22: UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET 2023-2030 (IN $ MILLION)
FIGURE
23: CANADA BIOENGINEERED PROTEIN DRUGS MARKET 2023-2030 (IN $ MILLION)
FIGURE
24: EUROPE BIOENGINEERED PROTEIN DRUGS MARKET, BY COUNTRY OUTLOOK, 2022 &
2030 (IN %)
FIGURE
25: UNITED KINGDOM BIOENGINEERED PROTEIN DRUGS MARKET 2023-2030 (IN $ MILLION)
FIGURE
26: GERMANY BIOENGINEERED PROTEIN DRUGS MARKET 2023-2030 (IN $ MILLION)
FIGURE
27: FRANCE BIOENGINEERED PROTEIN DRUGS MARKET 2023-2030 (IN $ MILLION)
FIGURE
28: SPAIN BIOENGINEERED PROTEIN DRUGS MARKET 2023-2030 (IN $ MILLION)
FIGURE
29: ITALY BIOENGINEERED PROTEIN DRUGS MARKET 2023-2030 (IN $ MILLION)
FIGURE
30: POLAND BIOENGINEERED PROTEIN DRUGS MARKET 2023-2030 (IN $ MILLION)
FIGURE
31: REST OF EUROPE BIOENGINEERED PROTEIN DRUGS MARKET 2023-2030 (IN $ MILLION)
FIGURE
32: ASIA-PACIFIC BIOENGINEERED PROTEIN DRUGS MARKET, BY COUNTRY OUTLOOK, 2022
& 2030 (IN %)
FIGURE
33: CHINA BIOENGINEERED PROTEIN DRUGS MARKET 2023-2030 (IN $ MILLION)
FIGURE
34: JAPAN BIOENGINEERED PROTEIN DRUGS MARKET 2023-2030 (IN $ MILLION)
FIGURE
35: INDIA BIOENGINEERED PROTEIN DRUGS MARKET 2023-2030 (IN $ MILLION)
FIGURE
36: SOUTH KOREA BIOENGINEERED PROTEIN DRUGS MARKET, 2023-2030 (IN $ MILLION)
FIGURE
37: ASEAN COUNTRIES BIOENGINEERED PROTEIN DRUGS MARKET 2023-2030 (IN $ MILLION)
FIGURE
38: AUSTRALIA & NEW ZEALAND BIOENGINEERED PROTEIN DRUGS MARKET 2023-2030
(IN $ MILLION)
FIGURE
39: REST OF ASIA-PACIFIC BIOENGINEERED PROTEIN DRUGS MARKET 2023-2030 (IN $
MILLION)
FIGURE
40: LATIN AMERICA BIOENGINEERED PROTEIN DRUGS MARKET, BY COUNTRY OUTLOOK, 2022
& 2030 (IN %)
FIGURE
41: BRAZIL BIOENGINEERED PROTEIN DRUGS MARKET 2023-2030 (IN $ MILLION)
FIGURE
42: MEXICO BIOENGINEERED PROTEIN DRUGS MARKET 2023-2030 (IN $ MILLION)
FIGURE
43: REST OF LATIN AMERICA BIOENGINEERED PROTEIN DRUGS MARKET 2023-2030 (IN $
MILLION)
FIGURE
44: MIDDLE EAST AND AFRICA BIOENGINEERED PROTEIN DRUGS MARKET, BY COUNTRY
OUTLOOK, 2022 & 2030 (IN %)
FIGURE
45: UNITED ARAB EMIRATES BIOENGINEERED PROTEIN DRUGS MARKET 2023-2030 (IN $
MILLION)
FIGURE
46: SAUDI ARABIA BIOENGINEERED PROTEIN DRUGS MARKET 2023-2030 (IN $ MILLION)
FIGURE
47: TURKEY BIOENGINEERED PROTEIN DRUGS MARKET 2023-2030 (IN $ MILLION)
FIGURE
48: SOUTH AFRICA BIOENGINEERED PROTEIN DRUGS MARKET 2023-2030 (IN $ MILLION)
FIGURE
49: REST OF MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET
2023-2030 (IN $ MILLION)